NCT01885117View on ClinicalTrials.gov

Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Human Influenza
Interventions
BIOLOGICAL

TIVf

Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)

Trial Locations (1)

20359

University Medical Center Hamburg-Eppendorf, Hamburg

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT01885117 - Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above | Biotech Hunter | Biotech Hunter